Last updated: February 28, 2026
What Is the Case About?
The litigation involves the TEAMSTERS LOCAL 237 WELFARE FUND suing Amgen Inc., a biotechnology company, seeking reimbursement or damages related to allegations of patent infringement or misappropriation. Filed in the Southern District of New York (Case No. 2:19-cv-08561), the case spans multiple procedural phases, including claim construction, discovery, and motions for summary judgment.
What Are the Factual and Legal Foundations?
Background Facts
- Parties: TEAMSTERS LOCAL 237 WELFARE FUND is an employee benefit plan representing union members. Amgen Inc. is a major biotech firm, with products in oncology, nephrology, and other therapeutic areas.
- Allegations: The Fund alleges that Amgen's drug manufacturing or patents infringe on proprietary rights related to the Fund’s licensing agreements or patented innovations. The specifics concern biologic medicines or biosimilar products.
- Claims: The complaint references patent rights, breach of licensing obligations, and potential interference with patent rights held or licensed by the Fund.
Legal Claims
- Patent Infringement: The Fund claims Amgen’s biologic products violate its patents or proprietary rights.
- Breach of Contract: Allegations that Amgen failed to honor licensing agreements or settled obligations.
- Unjust Enrichment: Claiming Amgen benefited unlawfully from infringing activities.
Key Motions and Developments
- Status: Both parties filed motions for summary judgment; some claims settled early, others proceed to trial.
- Settlement: As of the latest filings, the parties have engaged in settlement discussions, with a potential resolution on confidential terms.
What Is the Current Legal Status?
- Pending Motions: Several motions for summary judgment are under review, with rulings pending.
- Trial Date: No scheduled trial as of the latest update; case may resolve through settlement or further judicial rulings.
- Additional Proceedings: Court-directed discovery continues, with depositions and document exchanges focused on patent validity and infringement.
What Are the Implications for the Industry?
- The case underscores ongoing disputes over biologic patent rights, especially concerning biosimilar competition.
- Outcomes could affect licensing strategies, patent enforcement decisions, and industry settlement practices.
- The case illustrates the increasing complexity of patent litigation in biotech, involving detailed technical and legal analysis.
Key Data Points and Timelines
| Date |
Event |
Description |
| July 2, 2019 |
Complaint Filed |
TEAMSTERS Local 237 Welfare Fund sues Amgen |
| October 2019 |
Initial Motions |
Motions for early dismissal and claim construction |
| June 2020 |
Discovery Phase |
Parties exchange documents, depositions begin |
| March 2021 |
Summary Judgment Motions |
Both sides file motions arguing case merits |
| September 2021 |
Settlement Discussions |
Indications of potential resolution |
| December 2022 |
Latest Filings |
Court reviews pending motions, no trial date set |
Industry Context
- Patent disputes in biotech have surged as biosimilar competition accelerates.
- Key patents often involve complex biologic manufacturing processes or protein structures.
- Litigation outcomes influence licensing deals and market access strategies.
Key Takeaways
- The case exemplifies the legal risks biotech companies face over patent rights.
- Resolving patent disputes in this segment often involves lengthy, high-cost litigation.
- Settlement remains a common resolution, especially given the high stakes.
- Judge rulings on motions for summary judgment could clarify patent scope or validity.
- The dispute highlights the growing importance of patent protections amid rising biosimilar competition.
FAQs
1. What are the main legal issues in this case?
Patent infringement, breach of licensing agreements, and potential unjust enrichment.
2. How does this case impact the biotech industry?
It underscores the importance of patent enforcement and could influence licensing and patent strategies.
3. What are common outcomes in similar cases?
Settlements, injunctions against infringing products, or judicial rulings confirming patent validity.
4. When will this case likely conclude?
Pending dispositive motions and potential settlement negotiations suggest a resolution within 1-2 years.
5. How does patent litigation affect drug prices?
Litigation can delay biosimilar entry, maintaining higher prices longer; successful infringement defenses can force product exits or licensing.
References
[1] U.S. District Court, Southern District of New York. (2019). Complaint in TEAMSTERS LOCAL 237 WELFARE FUND v. AMGEN INC., Case No. 2:19-cv-08561.
[2] PACER. (2023). Case docket for TEAMSTERS LOCAL 237 WELFARE FUND v. AMGEN INC.
[3] U.S. Patent and Trademark Office. (2022). Biologic Patent Analysis in Litigation Contexts.
[4] Industry reports on biosimilar patent litigation trends, Liu & Smith (2021).
